Key facts
- This page summarizes Jay Donovan Wu's Form 3 filing for Ascendis Pharma A/S (ASND).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 18:06.
Jay Donovan Wu - 18 Mar 2026 Form 3 Insider Report for Ascendis Pharma A/S (ASND)
- Reporting relationship
- EVP & President US Market
- Issuer ticker
- ASND
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Michael Wolff Jensen as attorney-in-fact for Jay Wu
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jay Donovan Wu filed Form 3 for Ascendis Pharma A/S (ASND) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002079744
Primary reporting owner
Wu Jay Donovan
- Relationship
- EVP & President US Market
- Address
- C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK
- Signature
- /s/ Michael Wolff Jensen as attorney-in-fact for Jay Wu
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ASND
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,068
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ASND
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 45,078
- Exercise price
- $131.57
- Footnotes
- F2
ASND
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,333
- Exercise price
- Footnotes
- F3, F4
ASND
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 9,553
- Exercise price
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
Footnote F2
The warrants vested 25% on January 14, 2026 and thereafter in 36 equal monthly installments.
Footnote F3
The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
Footnote F4
Each restricted stock unit represents a contingent right to receive one ADS.
Footnote F5
The restricted stock units vest in three equal annual installments beginning on March 1, 2027.